Adam B. Weiner, Urologist at Cedars Sinai Medical Center, shared a post on X:
“ARTO long-term update in oligometastatic mCRPC:
SBRT to all mets + abi/ADT vs abi/ADT alone.
- 157 pts
- ≤3 bone/nodal mets
- Abiraterone + ADT ± MDT/SBRT
- Median follow-up: 53 mo
Results:
- OS: NR vs 50 mo
- HR 0.55, p=0.021
- bPFS: 44 vs 18 mo
- rPFS: 44 vs 17 mo
- PC-specific survival improved
- No major toxicity signal from adding SBRT
Big signal: MDT may be more than “delay next therapy” in oligometastatic CRPC.
Caveat: phase 2, unplanned OS analysis, not originally powered for OS.
Still hard to ignore”
Title: SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial
Authors: Giulio Francolini, Vanessa Di Cataldo, Saverio Caini, Pietro Garlatti, Michele Aquilano, Niccolò Bertini, Alessio Bruni, Gianluca Ingrosso, Rolando M. D’Angelillo, Luca Tagliaferri, Barbara A. Jereczek-Fossa, Matteo Augugliaro, Luca Triggiani, Silvana Parisi, Lorenzo Masieri, Riccardo Campi, Richard K. Valicenti, Gabriele Simontacchi, Daniela Greto, Pierluigi Bonomo, Mauro Loi, Chad Tang, Lorenzo Livi
Read the article.
Read also about ARTO Trial on OncoDaily.
